RxE2
- Company typePrivate
- Founded2020
- HeadquartersFargo, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
RxE2 firmographics
Firmographics- Name
- RxE2
- Legal name
- RxE2 Inc.
- Website
- https://rxe2.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
RxE2 industry classification
Industry- Product category
- Clinical Trial Technology
- NAICS
- Software Publishers (5132), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH)
- akta.pro secondary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where RxE2 is headquartered
LocationHeadquarters
- HQ city
- Fargo
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
RxE2 business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Clinical Trial Services Platform: RxE2 provides a comprehensive technology platform enabling community pharmacies to conduct clinical trial activities including recruitment, dispensing, counseling, and operational services for pharmaceutical and biotech sponsors.
- Pharmacy Network Services: RxE2 connects sponsors with network of thousands of pharmacies for direct patient access, decentralized trial visits, and recruitment services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free tier for current users with future paid model possible |
| Subscription | Annual | Enterprise pricing for pharmaceutical and biotech sponsors |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
RxE2 product offering
Product offeringCore offering
RxE2 is a technology platform that powers decentralized, community-based clinical trials by enabling independent community pharmacies to operate as clinical trial sites. The company connects pharmaceutical and biotech sponsors with a network of 1,200+ pharmacies for patient recruitment, dispensing of investigational products, counseling, and operational trial services, all driven by the proprietary AI-powered habitu platform.
Product overview
RxE2 is a technology platform that powers community-based clinical trials by enabling independent pharmacies to operate as next-generation clinical trial sites. The offering consists of a modular, multi-service architecture built around the core habítu AI platform, combined with service modules including E2 Recruitment (patient identification and enrollment), E2 Dispensing (investigational drug dispensing), E2 Counseling (patient education and compliance support), and the Clinical Trial Research Pharmacist (CTRP) certification program. The RxE2 Health mobile application connects participants, researchers, pharmacists, and family members. The Precision Dispensing methodology represents their supply chain innovation approach. Together, these components enable sponsors to leverage the trust and accessibility of community pharmacists for decentralized trial execution.
Differentiator
Problem solved
Functional benefit
Brands
- habitu: AI-powered technology platform acquired in 2021, focusing on habits and behaviors to create a Know Your Patient (KyP) engine enabled by artificial intelligence, improving patient outcomes with real-time analyses.
- E2 Recruitment
- E2 Dispensing
- E2 Counseling
- RxE2 Health
Products and services
- habitu Platform AI-powered technology platform focusing on people's habits and behaviors to create a Know Your Patient (KyP) engine that improves patient outcomes through real-time analyses. Used as the core intelligence layer for RxE2's decentralized clinical trial operations.
- E2 Recruitment Patient recruitment service enabling sponsors to connect with a network of thousands of community pharmacies for direct patient access in decentralized clinical trials.
- E2 Dispensing Clinical supplies dispensing service that enables community pharmacies to dispense investigational medicinal products (IMP) to clinical trial participants at the point of dispense.
- E2 Counseling Patient counseling service provided by community pharmacists to improve medication compliance and patient engagement in clinical trials.
- Clinical Trial Research Pharmacist (CTRP) Certification Specialized pharmacist certification and service model pioneered by RxE2 CEO Gerald Finken, recognizing pharmacists with specialized training in clinical research to improve patient recruitment, medication compliance, and retention in clinical trials.
- RxE2 Health Application Mobile application platform provided by RxE2 for clinical trial participants, researchers, pharmacists, and family members to access services, receive notifications, and manage trial participation.
Quantifiable outcome
- Addresses industry problem where 80% of traditional clinical trials finish late, often costing hundreds of millions of dollars
- +3 more outcomes
Companies that use RxE2
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
RxE2 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
RxE2 partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, flagship and minor.
- Habitu Ltd.coreRxE2 completed acquisition of Habitu Ltd., an Israeli-based technology company, in April 2021. Habitu's AI-powered technology platform focusing on habits and behaviors creates KyP (Know Your Patient) engine that improves patient outcomes through real-time analysis, enhancing RxE2's decentralized trial capabilities.
- Newdays PharmacyflagshipNewdays Pharmacy partnership enabling E2 Dispensing Service expansion to European Union and UK markets for clinical drug trials, marking RxE2's international expansion.
- CPESN USAcoreCPESN Networks partnership for pharmacy recruitment and network expansion, with booth presence at NCPA annual meetings (booths 1326-1327 in 2025).
- ESPhA (Enhanced Service Pharmacy Alliance)coreESPhA is the pharmacy industry's next-generation pharmacy service consulting firm. Gerald Finken appears on their podcast series discussing state pharmacy regulations and decentralized trials.
- Thrifty WhiteminorJeremy Faks, Director of Specialty Pharmacy at Thrifty White, participated in live discussion on regulations for investigational drugs and pharmacy dispensing vs GMP packaging.
- Decentralized Trials & Research Alliance (DTRA)coreCraig Lipset, Co-Founder and Co-Chair of DTRA, participated in RxE2 webinar discussing DCT evolution and community pharmacy integration, representing thought leadership partnership.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
RxE2 competitors and assessment
Company assessmentDirect peers
- Science 37: Direct competitor in decentralized clinical trials; Science 37 pioneered the "metasite" DCT model that enables patient participation from home, overlapping with RxE2's community-pharmacy-enabled decentralized approach for pharma sponsors.
- Medable: Leading decentralized clinical trial technology platform serving pharma sponsors with eCOA, eConsent, telehealth, and remote data capture—overlapping with RxE2's modular platform for decentralized trial execution.
- Curebase: Decentralized clinical trial software and services company enabling sponsors to run fully virtual and hybrid trials; competes for similar pharma sponsor budgets as RxE2's pharmacy-enabled DCT offering.
- THREAD Research: Provides a decentralized clinical trial platform (eCOA, ePRO, eConsent, telemedicine) used by pharma and biotech sponsors; competes for the same DCT technology budget as RxE2.
Broad incumbents
- CVS Health Clinical Trials Services: CVS operates retail pharmacy-based clinical trial services through its MinuteClinic and Research Institute arms; represents a scaled incumbent competitor to RxE2's community-pharmacy-as-trial-site model with far greater resources.
- Walgreens Clinical Trials: Walgreens has built a clinical trial business leveraging its national retail pharmacy footprint, directly competing with RxE2's value proposition of using community pharmacies to recruit and conduct decentralized trials.
- IQVIA: World's largest CRO offering decentralized trial capabilities alongside full-service clinical development; competes with RxE2 for pharma sponsor DCT contracts at the enterprise end of the market.
- ICON plc: Global CRO with dedicated decentralized and hybrid trial offerings post-PRA Health and Symphony Health acquisitions; competes for the same pharma sponsor relationships RxE2 targets.
Emerging players
- SiteRx: Site network management platform focused on connecting sponsors with community-based research sites; shares RxE2's thesis of expanding trials beyond academic medical centers.
Others
- Clinical Trials Research Pharmacist (CTRP) Program — National Association of Boards of Pharmacy / ACPE accredited training programs: Adjacent ecosystem participant: continuing education and pharmacist certification programs for clinical research; relevant because RxE2's CTRP® service mark leverages pharmacist credentialing infrastructure.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
RxE2 social profiles
Digital presenceRxE2 financial estimates
Financial estimateRevenue estimate
Valuation estimate
RxE2 leadership team
Management profileNumber of profiles
Profiles5 records
RxE2 subsidiaries and ownership
Company hierarchySubsidiaries1 record
RxE2 funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RxE2 M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RxE2
What does RxE2 do?
RxE2 is a technology platform that powers decentralized, community-based clinical trials by enabling independent community pharmacies to operate as clinical trial sites. The company connects pharmaceutical and biotech sponsors with a network of 1,200+ pharmacies for patient recruitment, dispensing of investigational products, counseling, and operational trial services, all driven by the proprietary AI-powered habitu platform.
Is RxE2 a public or private company?
RxE2 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RxE2 founded?
RxE2 was founded in 2020. It employs 11 to 50 people.
Where is RxE2 based?
RxE2 is headquartered in Fargo, United States, in the North America region.
How does RxE2 make money?
Two revenue lines are on record. Clinical Trial Services Platform is the primary driver. The others are pharmacy Network Services.
Who are RxE2's main competitors?
Direct peers on record are Science 37, Medable, Curebase and THREAD Research. Broad incumbents are CVS Health Clinical Trials Services, Walgreens Clinical Trials, IQVIA and ICON plc. SiteRx is listed as an emerging player. Clinical Trials Research Pharmacist (CTRP) Program — National Association of Boards of Pharmacy / ACPE accredited training programs is listed as an others.
Does RxE2 have an API?
No public API is recorded for RxE2.
What industry is RxE2 in?
RxE2's product category is Clinical Trial Technology. Its primary akta.pro industry code is HLAGACAH, Decentralized & Hybrid Trial Site Services (Home Health/Nursing), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5132 and its SIC code is 7372.